In the Specification:

Please delete the Cross-Reference to Related Applications section on page 1, lines 5-11, and replace it with the following paragraph.

This application is a continuation-in-part application claiming priority from U.S.S.N. 60/103,098, filed on October 5, 1998, and from U.S.S.N. 09/022,965, filed on February 12, 1998, which is a continuation-in-part application of U.S.S.N. 08/532,979, filed September 22, 1995, which issued as U.S. Patent No. 5,969,117, which is a continuation-in-part application of U.S.S.N. 08/516,454 filed August 17, 1995, which issued as U.S. Patent No. 5,652,356.

Please delete the first entry in Table 1 at page 22 and replace it with the following:

164	GCG TGC CTC CTC ACT GGC	Antisense	1

Please delete the heading at page 36, lines 26-27 and replace it with the following heading:

In Vitro Complement Activation Studies

Please delete the paragraphs at page 36, line 29 to page 48, line 26. In accordance with 37 C.F.R. § 1.121(b)(1)(iii), a marked up version is not provided for deleted paragraphs.

Please delete the paragraph at page 58, line 25 to page 59, line 20, and replace it with the following:

LS-174T human colon carcinoma cells (1×10^6 cells) were inoculated subcutaneously (s.c.) into the left flank of athymic mice. A single dose of RI_α antisense hybrid (Oligo 165, SEQ ID NO:4), inverted hybrid (Oligo 166, SEQ ID NO:6), or antisense (Oligo 164, SEQ ID NO:1) oligonucleotides or control oligonucleotide (Oligo 169, SEQ ID NO:7);

Oligo 168 (SEQ ID NO:5); Oligo 188, (SEQ ID NO:3) as shown in Table 1 (1 mg per 0.1 ml saline per mouse), or saline (0.1 ml per mouse), was injected s.c. into the right flank of mice when tumor size reached 80 to 100 mg, about 1 week after cell inoculation. Tumor volumes were obtained from daily measurement of the longest and shortest diameters and calculation by the formula, $4/3\pi r^3$ where r = (length + width)/4. At each indicated time, two animals from the control and antisense-treated groups were killed, and tumors were removed and weighed. The results are shown in FIG. 1. These results show that the size of the tumor in the animal treated with the inverted hybrid oligonucleotide 166 having SEQ ID NO:6 was surprisingly smaller from three days after injection onward than the phosphorothioate oligonucleotide 164 having SEQ ID NO:1. That this effect was sequence-specific is also demonstrated in FIG. 1: control oligonucleotide 168 (SEQ ID NO:5) has little ability to keep tumor size at a minimum relative to the hybrid and inverted hybrid oligonucleotides.

REMARKS

Claims 1-20, 23-33 are pending in the application. Applicant notes that claims 21 and 22 were cancelled in the response filed March 26, 2001, without prejudice or disclaimer of the subject matter contained therein.

The specification has been amended to correct the Cross-Reference to Related Applications section to indicate applications that have issued as patents and to correct the omission of an additional related patent. As it appears that the marked up version of the previous amendment to the Cross-Reference to Related Applications section made in the response filed on March 26, 2001, inadvertently did not indicate the